Evaluation of the Immunogenicity and Efficacy of HIV-1 SOSIP Envelope Protein Vaccine Delivered with or without Recombinant Viral Vector Vaccines

开发有效的艾滋病毒疫苗和其他预防策略依赖于在临床前研究中使用非人灵长类动物。为了满足这一需求，类人猿疫苗评估单位（sveu）提供了主要支持艾滋病疫苗和预防方式临床前评估的NHP资源。SVEU项目将为NIAID提供使用NHP模型评估候选艾滋病疫苗的能力，在该模型中，可以对全身和粘膜免疫反应进行全面评估，可以轻松测试疫苗的有效性，可以确定降低病毒获得风险的相关因素，并可以开展增强临床疫苗免疫原性和有效性的方法。sveu将为美国国立卫生研究院支持的研究人员提供反应灵敏、灵活的疫苗资源，并可支持艾滋病疫苗研究的所有阶段，从临床前评估或候选艾滋病疫苗的临床试验，目的是确定一种疫苗，该疫苗将产生能够预防或控制病毒感染的免疫反应。sveu的范围包括为国家卫生保健计划提供住房和维持，开展支持艾滋病预防研究（重点是艾滋病疫苗）的研究，支持一个国家卫生保健计划繁殖地，以及这些活动的一般行政和管理。

The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prevention modalities. The SVEU program will provide NIAID the ability to evaluate candidate AIDS vaccines using NHP models in which thorough evaluations of systemic and mucosal immune responses can be conducted, vaccine efficacy can easily be tested, correlates of reduced risk of virus acquisition can be identified, and approaches to enhance immunogenicity and efficacy of clinical vaccines can be conducted. The SVEUs will provide a responsive, flexible vaccine resource that is available to NIH-supported researchers and can support all stages of AIDS vaccine research, from preclinical evaluation or clinical testing of candidate AIDS vaccines, with the objective of identifying a vaccine that will generate immune responses able to prevent or control viral infection. The scope of the SVEUs includes housing and maintenance of NHPs, the conduct of studies supporting AIDS prevention research, with an emphasis on AIDS vaccines, support of a NHP breeding colony, and general administration and management of these activities.